Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ikena Oncology Inc (IKNA)

Ikena Oncology Inc (IKNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,073
  • Shares Outstanding, K 48,258
  • Annual Sales, $ 9,160 K
  • Annual Income, $ -68,170 K
  • 60-Month Beta 0.49
  • Price/Sales 8.85
  • Price/Cash Flow N/A
  • Price/Book 0.53
Trade IKNA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.37
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +29.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +32.81%
on 05/28/24
1.8900 -10.05%
on 06/12/24
+0.3700 (+27.82%)
since 05/24/24
3-Month
1.2200 +39.34%
on 04/18/24
1.8900 -10.05%
on 06/12/24
+0.3100 (+22.30%)
since 03/26/24
52-Week
1.0200 +66.67%
on 11/09/23
7.0000 -75.71%
on 06/29/23
-4.6900 (-73.40%)
since 06/26/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of...

IKNA : 1.6800 (+0.60%)
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Advancement across Company’s pipeline towards regulatory and data milestones...

IKNA : 1.6800 (+0.60%)
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 1.6800 (+0.60%)
Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 1.6800 (+0.60%)
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary...

IKNA : 1.6800 (+0.60%)
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier...

IKNA : 1.6800 (+0.60%)
Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration

Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena’s and VHIO’s leadership in research, translational science, and...

IKNA : 1.6800 (+0.60%)
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development...

IKNA : 1.6800 (+0.60%)
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into...

IKNA : 1.6800 (+0.60%)
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed...

IKNA : 1.6800 (+0.60%)

Business Summary

Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States....

See More

Key Turning Points

3rd Resistance Point 1.7075
2nd Resistance Point 1.6937
1st Resistance Point 1.6869
Last Price 1.6800
1st Support Level 1.6663
2nd Support Level 1.6525
3rd Support Level 1.6457

See More

52-Week High 7.0000
Fibonacci 61.8% 4.7156
Fibonacci 50% 4.0100
Fibonacci 38.2% 3.3044
Last Price 1.6800
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar